Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma

Detalles Bibliográficos
Autores principales: Jia, Wenqing, Liu, Zhuoran, Zhan, Ling, Zhao, Qiwu, Qiu, Weihua, Kuang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657471/
https://www.ncbi.nlm.nih.gov/pubmed/36362609
http://dx.doi.org/10.3390/jcm11216380
_version_ 1784829702966345728
author Jia, Wenqing
Liu, Zhuoran
Zhan, Ling
Zhao, Qiwu
Qiu, Weihua
Kuang, Jie
author_facet Jia, Wenqing
Liu, Zhuoran
Zhan, Ling
Zhao, Qiwu
Qiu, Weihua
Kuang, Jie
author_sort Jia, Wenqing
collection PubMed
description
format Online
Article
Text
id pubmed-9657471
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96574712022-11-15 Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma Jia, Wenqing Liu, Zhuoran Zhan, Ling Zhao, Qiwu Qiu, Weihua Kuang, Jie J Clin Med Editorial MDPI 2022-10-28 /pmc/articles/PMC9657471/ /pubmed/36362609 http://dx.doi.org/10.3390/jcm11216380 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Editorial
Jia, Wenqing
Liu, Zhuoran
Zhan, Ling
Zhao, Qiwu
Qiu, Weihua
Kuang, Jie
Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
title Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
title_full Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
title_fullStr Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
title_full_unstemmed Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
title_short Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
title_sort editorial: apatinib and anlotinib in the treatment of radioactive iodine refractory and highly invasive thyroid carcinoma
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657471/
https://www.ncbi.nlm.nih.gov/pubmed/36362609
http://dx.doi.org/10.3390/jcm11216380
work_keys_str_mv AT jiawenqing editorialapatinibandanlotinibinthetreatmentofradioactiveiodinerefractoryandhighlyinvasivethyroidcarcinoma
AT liuzhuoran editorialapatinibandanlotinibinthetreatmentofradioactiveiodinerefractoryandhighlyinvasivethyroidcarcinoma
AT zhanling editorialapatinibandanlotinibinthetreatmentofradioactiveiodinerefractoryandhighlyinvasivethyroidcarcinoma
AT zhaoqiwu editorialapatinibandanlotinibinthetreatmentofradioactiveiodinerefractoryandhighlyinvasivethyroidcarcinoma
AT qiuweihua editorialapatinibandanlotinibinthetreatmentofradioactiveiodinerefractoryandhighlyinvasivethyroidcarcinoma
AT kuangjie editorialapatinibandanlotinibinthetreatmentofradioactiveiodinerefractoryandhighlyinvasivethyroidcarcinoma

Ejemplares similares